The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing
Open accessAbstract
The discovery of CRISPR/Cas has revolutionized the field of genome editing. CRIPSR/Cas components are part of the bacterial immune system and are able to induce double-strand DNA breaks in the genome, which are resolved by endogenous DNA repair mechanisms. The most relevant of these are the error-prone nonhomologous end joining and homology directed repair pathways. The former can lead to gene knockout by introduction of insertions and deletions at the cut site, while the latter can be used for gene correction based on a provided repair template. In this Account, we focus on the delivery aspects of CRISPR/Cas for therapeutic applications in vivo. Safe and effective delivery of the CRISPR/Cas components into the nucleus of affected cells is essential for therapeutic gene editing. These components can be delivered in several formats, such as pDNA, viral vectors, or ribonuclear complexes. In the ideal case, the delivery system should address the current limitations of CRISPR gene editing, which are (1) lack of targeting specific tissues or cells, (2) the inability to enter cells, (3) activation of the immune system, and (4) off-target events. To circumvent most of these problems, initial therapeutic applications of CRISPR/Cas were performed on cells ex vivo via classical methods (e.g., microinjection or electroporation) and novel methods (e.g., TRIAMF and iTOP). Ideal candidates for such methods are, for example, hematopoietic cells, but not all tissue types are suited for ex vivo manipulation. For direct in vivo application, however, delivery systems are needed that can target the CRISPR/Cas components to specific tissues or cells in the human body, without causing immune activation or causing high frequencies of off-target effects. Viral systems have been used as a first resort to transduce cells in vivo. These systems suffer from problems related to packaging constraints, immunogenicity, and longevity of Cas expression, which favors off-target events. Viral vectors are as such not the best choice for direct in vivo delivery of CRISPR/Cas. Synthetic vectors can deliver nucleic acids as well, without the innate disadvantages of viral vectors. They can be classed into lipid, polymeric, and inorganic particles, all of which have been reported in the literature. The advantage of synthetic systems is that they can deliver the CRISPR/Cas system also as a preformed ribonucleoprotein complex. The transient nature of this approach favors low frequencies of off-target events and minimizes the window of immune activation. Moreover, from a pharmaceutical perspective, synthetic delivery systems are much easier to scale up for clinical use compared to viral vectors and can be chemically functionalized with ligands to obtain target cell specificity. The first preclinical results with lipid nanoparticles delivering CRISPR/Cas either as mRNA or ribonucleoproteins are very promising. The goal is translating these CRISPR/Cas therapeutics to a clinical setting as well. Taken together, these current trends seem to favor the use of sgRNA/Cas ribonucleoprotein complexes delivered in vivo by synthetic particles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Banaszynski, L. A., Chen, L.-C., Maynard-Smith, L. A., Ooi, A. G. L., & Wandless, T. J. (2006) · Cell · doi:10.1016/j.cell.2006.07.025 · Cited by 902
Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.014 · Cited by 878
Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects
Shen, B., Zhang, W., Zhang, J., Zhou, J., Wang, J., Chen, L., Wang, L., Hodgkins, A., Iyer, V., Huang, X., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2857 · Cited by 769
Lee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0137-2 · Cited by 755
A split-Cas9 architecture for inducible genome editing and transcription modulation
Zetsche, B., Volz, S. E., & Zhang, F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3149 · Cited by 710
Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
Ramakrishna, S., Kwaku Dad, A.-B., Beloor, J., Gopalappa, R., Lee, S.-K., & Kim, H. (2014) · Genome Research · doi:10.1101/gr.171264.113 · Cited by 655
Self‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629
Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles
Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624
Kedmi, R., Ben-Arie, N., & Peer, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.027 · Cited by 546
Alsaiari, S. K., Patil, S., Alyami, M., Alamoudi, K. O., Aleisa, F. A., Merzaban, J. S., Li, M., & Khashab, N. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11754 · Cited by 517
CasX enzymes comprise a distinct family of RNA-guided genome editors
Liu, J.-J., Orlova, N., Oakes, B. L., Ma, E., Spinner, H. B., Baney, K. L. M., Chuck, J., Tan, D., Knott, G. J., Harrington, L. B., et al. (2019) · Nature · doi:10.1038/s41586-019-0908-x · Cited by 446
High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population
Wagner, D. L., Amini, L., Wendering, D. J., Burkhardt, L.-M., Akyüz, L., Reinke, P., Volk, H.-D., & Schmueck-Henneresse, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0204-6 · Cited by 399
Colamonici, O. R., Domanski, P., Sweitzer, S. M., Larner, A., & Buller, R. M. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.27.15974 · Cited by 386
Disabling Cas9 by an anti-CRISPR DNA mimic
Shin, J., Jiang, F., Liu, J.-J., Bray, N. L., Rauch, B. J., Baik, S. H., Nogales, E., Bondy-Denomy, J., Corn, J. E., & Doudna, J. A. (2017) · Science Advances · doi:10.1126/sciadv.1701620 · Cited by 354
Wang, D., Mou, H., Li, S., Li, Y., Hough, S., Tran, K., Li, J., Yin, H., Anderson, D. G., Sontheimer, E. J., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.087 · Cited by 345
Efficient Intracellular Delivery of Native Proteins
D’Astolfo, D. S., Pagliero, R. J., Pras, A., Karthaus, W. R., Clevers, H., Prasad, V., Lebbink, R. J., Rehmann, H., & Geijsen, N. (2015) · Cell · doi:10.1016/j.cell.2015.03.028 · Cited by 338
Gene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301
Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs
Ryan, D. E., Taussig, D., Steinfeld, I., Phadnis, S. M., Lunstad, B. D., Singh, M., Vuong, X., Okochi, K. D., McCaffrey, R., Olesiak, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1199 · Cited by 280
Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions
Lübbers, J., Rodríguez, E., & van Kooyk, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02807 · Cited by 260
Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA
Patel, S., Ashwanikumar, N., Robinson, E., DuRoss, A., Sun, C., Murphy-Benenato, K. E., Mihai, C., Almarsson, Ö., & Sahay, G. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b02664 · Cited by 251
Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population
Simhadri, V. L., McGill, J., McMahon, S., Wang, J., Jiang, H., & Sauna, Z. E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.006 · Cited by 241
Partial DNA-guided Cas9 enables genome editing with reduced off-target activity
Yin, H., Song, C.-Q., Suresh, S., Kwan, S.-Y., Wu, Q., Walsh, S., Ding, J., Bogorad, R. L., Zhu, L. J., Wolfe, S. A., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2559 · Cited by 240
CRISPR off-target analysis in genetically engineered rats and mice
Anderson, K. R., Haeussler, M., Watanabe, C., Janakiraman, V., Lund, J., Modrusan, Z., Stinson, J., Bei, Q., Buechler, A., Yu, C., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0011-5 · Cited by 216
Quantifying on- and off-target genome editing
Hendel, A., Fine, E. J., Bao, G., & Porteus, M. H. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.12.001 · Cited by 167
Kouranova, E. V., Forbes, K. P., Zhao, G., Warren, J., Bartels, A., Wu, Y., & Cui, X. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.009 · Cited by 167
Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization
Senturk, S., Shirole, N. H., Nowak, D. G., Corbo, V., Pal, D., Vaughan, A., Tuveson, D. A., Trotman, L. C., Kinney, J. B., & Sordella, R. (2017) · Nature Communications · doi:10.1038/ncomms14370 · Cited by 166
Immunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 163
Lattanzi, A., Meneghini, V., Pavani, G., Amor, F., Ramadier, S., Félix, T., Antoniani, C., Masson, C., Alibeu, O., Lee, C. M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.008 · Cited by 149
Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells
Hung, K. L., Meitlis, I., Hale, M. R., Chen, C., Singh, S., Jackson, S. W., Miao, C. H., Khan, I., Rawlings, D. J., & James, R. G. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.012 · Cited by 143
Grenier, P., Viana, I. M. D. O., Lima, E. M., & Bertrand, N. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.022 · Cited by 139
Chang, J., Chen, X., Glass, Z., Gao, F., Mao, L., Wang, M., & Xu, Q. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00493 · Cited by 134
Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA
Kretzmann, J. A., Ho, D., Evans, C. W., Plani-Lam, J. H. C., García‐Bloj, B., Mohamed, A. E., O’Mara, M. L., Ford, E., Tan, D. E. K., Lister, R., et al. (2017) · Chemical Science · doi:10.1039/c7sc00097a · Cited by 130
The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes
Mérienne, N., Vachey, G., de Longprez, L., Meunier, C., Zimmer, V., Perriard, G., Canales, M., Mathias, A., Herrgott, L., Beltraminelli, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.075 · Cited by 130
Genome editing by natural and engineered CRISPR-associated nucleases
Wu, W. Y., Lebbink, J. H. G., Kanaar, R., Geijsen, N., & John van der, O. O. S. T. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0080-x · Cited by 124
Hsieh, Y.-C., Wang, H.-E., Lin, W.-W., Roffler, S. R., Cheng, T.-C., Su, Y.-C., Li, J.-J., Chen, C., Huang, C.-H., Chen, B., et al. (2018) · Theranostics · doi:10.7150/thno.22164 · Cited by 116
Cationic Polymer‐Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing
Zhang, Z., Wan, T. Y., Chen, Y., Chen, Y., Sun, H., Cao, T., Songyang, Z., Tang, G., Wu, C., Yuan, P., et al. (2018) · Macromolecular Rapid Communications · doi:10.1002/marc.201800068 · Cited by 113
Biased and unbiased methods for the detection of off-target cleavage by CRISPR/Cas9: An overview
Martin, F., Sánchez-Hernández, S., Gutiérrez-Guerrero, A., Pinedo-Gomez, J., & Benabdellah, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091507 · Cited by 92
Bhattacharyya, S., Wang, W., Tamaki, Z., Shi, B., Yeldandi, A. V., Tsukimi, Y., Yamasaki, M., & Varga, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02434 · Cited by 84
Yen, J. S., Fiorino, M., Liu, Y., Paula, S., Clarkson, S., Quinn, L., Tschantz, W. R., Klock, H. E., Guo, N., Russ, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34601-6 · Cited by 70
CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential
Blenke, E. O., Evers, M. J. W., Mastrobattista, E., & John van der, O. O. S. T. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.002 · Cited by 65
Self-citationBroering, R., Real, C. I., John, M., Jahn‐Hofmann, K., Ickenstein, L. M., Kleinehr, K., Paul, A., Sutter, K., Dittmer, U., Gerken, G., et al. (2013) · International Immunology · doi:10.1093/intimm/dxt040 · Cited by 62
Design and assessment of engineered CRISPR–Cpf1 and its use for genome editing
Li, B., Zeng, C., & Dong, Y. (2018) · Nature Protocols · doi:10.1038/nprot.2018.004 · Cited by 52
Clinical applications of CRISPR‐based genome editing and diagnostics
Foss, D. V., Hochstrasser, M. L., & Wilson, R. C. (2019) · Transfusion · doi:10.1111/trf.15126 · Cited by 51
Lessons learned from lung and liver in-vivo gene therapy: implications for the future
van Haasteren, J., Hyde, S. C., & Gill, D. R. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1506761 · Cited by 47
Microinjection and Micromanipulation: A Historical Perspective
Xu, W. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8831-0_1 · Cited by 45
Overview of Drug Delivery and Alternative Methods to Electroporation
Hui, S. W. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-194-9_6 · Cited by 44
siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease
Thi, E. P., Mire, C. E., Lee, A. C. H., Geisbert, J. B., Ursic-Bedoya, R. J., Agans, K. N., Robbins, M., Deer, D. J., Cross, R. W., Kondratowicz, A. S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci96185 · Cited by 43
CRISPR/Cas9 genome engineering in hematopoietic cells
Sürün, D., von Melchner, H., & Schnütgen, F. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.08.001 · Cited by 16
Targeted Genome Editing Using DNA-Free RNA-Guided Cas9 Ribonucleoprotein for CHO Cell Engineering
Shin, J., Lee, N., Cho, S., & Cho, B. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7795-6_8 · Cited by 12
Cited by
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9450 · Cited by 614
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
Uddin, F., Rudin, C. M., & Sen, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01387 · Cited by 581
Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.05.032 · Cited by 516
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
Analytical characterization of liposomes and other lipid nanoparticles for drug delivery
Fan, Y., Marioli, M., & Zhang, K. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113642 · Cited by 395
Metadata
- Authors
- Wilbie, D., Walther, J., & Mastrobattista, E.
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-05-17
- Volume
- 52
- Issue
- 6
- Pages
- 1555-1564
- ISSN
- 0001-4842 (ISSN-L)
- 1520-4898
- OpenAlex
- W2945739890
- Cited by
- 294
- References
- 60
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.